FIELD: pharmaceutical industry; ophthalmic pharmaceutical composition and its applications.
SUBSTANCE: ophthalmic topical pharmaceutical composition containing a phospholipid nanoemulsion with vitamin D in the range from 0.02 to 1.4 wt./vol.% and phospholipids in the range from 0.1 to 5 wt./vol.%, where the emulsified particles have the size particles ranging from 100 to 300 nanometers in diameter, and phospholipids and vitamin D are in a ratio of at least 3:1. Use of said pharmaceutical composition for storing or maintaining isolated corneas; use of an ophthalmic pharmaceutical composition for the manufacture of a topical medicinal product for reducing the absorption of light in the wavelength range of 220-520 nm in the eyes; use of an ophthalmic pharmaceutical composition for manufacturing of a topical medicament for improved delivery of vitamin D to the eyes; use of an ophthalmic pharmaceutical composition for manufacturing of a topical medicinal product for treatment of an eye disease or condition.
EFFECT: use of the group of inventions provides local therapy that does not cause irritation, has increased duration, sufficient to improve the diffusion of lipophilic agents into the epithelial layers of the cornea and into the posterior segment of the eye.
23 cl, 12 dwg, 9 tbl
Title | Year | Author | Number |
---|---|---|---|
OPHTHALMOLOGICAL COMPOSITIONS | 2017 |
|
RU2756758C2 |
ESTERS FOR TREATMENT OF OPHTHALMOLOGICAL INFLAMMATORY DISEASES | 2012 |
|
RU2640506C9 |
ESTERS FOR TREATING OPHTHALMIC INFLAMMATORY DISEASES | 2012 |
|
RU2707961C2 |
BIS-NAPHTHAZARIN BASED AGENT AND METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2669374C2 |
LIPID-BASED OPHTHALMIC EMULSION | 2019 |
|
RU2793333C2 |
ESTERS FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISEASES | 2012 |
|
RU2747953C2 |
THERAPEUTIC RECOVERY AND ENHANCEMENT OF OCULAR SURFACE WETTING | 2009 |
|
RU2510274C2 |
COMPOUND ETHERS FOR TREATMENT OF OPHTHALMOLOGICAL INFLAMMATORY DISEASES | 2012 |
|
RU2673230C1 |
ESTERS FOR OPHTHALMOLOGICAL INFLAMMATORY DISEASES TREATMENT | 2012 |
|
RU2627438C2 |
EYE DROPS BASED ON COMPOSITION OF PHARMACEUTICALLY ACCEPTABLE ADDITIVE ACID SALTS AND METHYLETHYL PYRIDONOL AND TAURINE CONTAINING COMPOSITION OF GROUP B VITAMINS | 2013 |
|
RU2533276C1 |
Authors
Dates
2024-01-22—Published
2019-12-06—Filed